Overview
Acceleration and Relapse Prevention With Triiodothyronine (T3) as an Adjunct to Electroconvulsive Therapy (ECT)
Status:
Completed
Completed
Trial end date:
2012-04-01
2012-04-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
The purpose of this study is: - To evaluate liothyronine (Cytomel) as an accelerating agent (i.e. faster rate to clinical remission) to electroconvulsive therapy. - To evaluate whether thyroid supplement acceleration can reduce the neurocognitive side effect of ECT treatment. - To evaluate whether thyroid status at the time of remission is associated with subsequent relapse rate. - To evaluate genetic polymorphisms in enzymes responsible for thyroid metabolism and the serotonin transporter promoter gene in depression (5-HTTLRP).Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Mayo Clinic
Criteria
Inclusion Criteria:- Ages 18-64, male and female, any race/ethnicity
- Current diagnosis of major depression (unipolar)
- Currently Hospitalized at Mayo Clinic Physician recommendation for ECT treatment at
Mayo Clinic
- Willing to return to Mayo Clinic for follow-up
Exclusion Criteria:
- Inability to speak English
- Inability or unwillingness to provide written informed consent
- Psychotic depression (SCID-confirmed)
- Court-ordered involuntary ECT
- Currently receiving maintenance ECT
- Unstable current medical condition
- A condition that would deem triiodothyronine treatment unsafe
- Diagnosis of primary thyroid disorder
- Lithium treatment within 6 weeks of randomization
- Currently taking levothyroxine (Synthroid®) or triiodothyronine (Cytomel®)
- Subclinical hypo- or hyperthyroidism
- History of atrial fibrillation or any cardiac arrhythmia except sinus bradycardia
- History of myocardial infarction within the past 12 months or unstable coronary artery
disease
- Pregnancy
- History of Osteoporosis